Top

Published in:

01-06-2020 | Metastasis | Original Article

Histopathological and molecular study for synchronous lung adenocarcinoma staging

Authors: Elsa Donfrancesco, Violaine Yvorel, François Casteillo, Marie-Laure Stachowicz, Arnaud Patoir, Olivier Tiffet, Michel Péoc’h, Fabien Forest

Published in: Virchows Archiv | Issue 6/2020

Abstract

The presence of multiple synchronous lung cancer with the same histopathological type for a patient is a common situation and an issue for staging. Pathological criteria exist to distinguish multiple primaries from intra-pulmonary metastases of the same tumor, but they lack standardization. We wondered how molecular analysis with a limited Next Generation Sequencing panel could bring further information for tumor staging in this setting. We analyzed 24 patients with a total of 50 tumor nodules (22 pairs, two triplets). We compared histopathological examination with molecular analysis. A total of 50 tumors were molecularly tested. Nucleoli size was associated with molecular analysis concordance (p = 0.047). The presence of lepidic component in any of the two larger tumors was associated with molecular analysis concordance (p = 0.012). For molecular analysis, the proportion of progression-free patients was at the limits of significance (p = 0.054) whereas the presence of lepidic component, architectural concordance, and the concordance of comprehensive histologic assessments was not related to progression-free survival. For two patients with a discordant TTF-1 immunohistochemistry, molecular analysis showed a different mutation. Our results show that a limited NGS panel brings supplementary data to classify synchronous lung adenocarcinoma in most patients. We show that molecular staging seems in accordance with progression-free survival. Histopathological examination alone might not be accurate enough to assess a correct staging for synchronous tumors. We also suggest that TTF-1 immunohistochemistry, for the rare discrepant cases, might be a surrogate to molecular analysis.

Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA (2018) Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung. J Thorac Oncol 13:205–217. https://doi.org/10.1016/j.jtho.2017.10.019 CrossRefPubMed

Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, Travis WD (2009) Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 33:1752–1764. https://doi.org/10.1097/PAS.0b013e3181b8cf03 CrossRefPubMedPubMedCentral

Travis WD et al (2015) WHO classification of tumours of the lung, pleura, thymus and heart. International Agency for Research on Cancer, Lyon

Martini N, Melamed MR (1975) Multiple primary lung cancers. J Thorac Cardiovasc Surg 70:606–612CrossRef

Murphy SJ, Aubry MC, Harris FR, Halling GC, Johnson SH, Terra S, Drucker TM, Asiedu MK, Kipp BR, Yi ES, Peikert T, Yang P, Vasmatzis G, Wigle DA (2014) Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. J Clin Oncol 32:4050–4058. https://doi.org/10.1200/JCO.2014.56.7644 CrossRefPubMedPubMedCentral

Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H (2017) Utility of genomic analysis in differentiating synchronous and metachronous lung adenocarcinomas from primary adenocarcinomas with intrapulmonary metastasis. Transl Oncol 10:442–449. https://doi.org/10.1016/j.tranon.2017.02.009 CrossRefPubMedPubMedCentral

Mansuet-Lupo A, Barritault M, Alifano M, et al (2019) Proposal for a combined histomolecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors. J Thorac Oncol 1–13. doi: https://doi.org/10.1016/j.jtho.2019.01.017

Chang JC, Alex D, Bott M et al (2019) Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intra-pulmonary metastases: comparison with standard histopathologic approach. Clin Cancer Res 129243:clincanres.1700.2019. https://doi.org/10.1158/1078-0432.ccr-19-1700 CrossRef

Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S, Flieder D, Gazdar A, Geisinger K, Hasleton P, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Motoi N, Nicholson AG, Noguchi M, Nonaka D, Pelosi G, Petersen I, Rekhtman N, Roggli V, Travis WD, Tsao MS, Wistuba I, Xu H, Yatabe Y, Zakowski M, Witte B, Kuik DJ (2012) Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 25:1574–1583. https://doi.org/10.1038/modpathol.2012.106 CrossRefPubMedPubMedCentral

10.

Wu C, Zhao C, Yang Y, He Y, Hou L, Li X, Gao G, Shi J, Ren S, Chu H, Zhou C, Zhang J, Schmid-Bindert G (2015) High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules. J Thorac Oncol 10:778–783. https://doi.org/10.1097/JTO.0000000000000487 CrossRefPubMed

11.

Asmar R, Sonett JR, Singh G, Mansukhani MM, Borczuk AC (2017) Use of oncogenic driver mutations in staging of multiple primary lung carcinomas: a single-center experience. J Thorac Oncol 12:1524–1535. https://doi.org/10.1016/j.jtho.2017.06.012 CrossRefPubMed

12.

Schneider F, Derrick V, Davison JM, Strollo D, Incharoen P, Dacic S (2016) Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Mod Pathol 29:735–742. https://doi.org/10.1038/modpathol.2016.66 CrossRefPubMed

13.

Warth A, Macher-Goeppinger S, Muley T, Thomas M, Hoffmann H, Schnabel PA, Penzel R, Schirmacher P, Aulmann S (2012) Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur Respir J 39:1437–1442. https://doi.org/10.1183/09031936.00105911 CrossRefPubMed

14.

Forest F, Stachowicz M-L, Casteillo F, Karpathiou G, Gouzy-Grosjean F, Guilaubey C, Cottier M, Beal J, Clemenson A, Péoc’h M (2017) EGFR , KRAS , BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies. Exp Mol Pathol 103:306–310. https://doi.org/10.1016/j.yexmp.2017.11.013 CrossRefPubMed

15.

Arai J, Tsuchiya T, Oikawa M, Mochinaga K, Hayashi T, Yoshiura K, Tsukamoto K, Yamasaki N, Matsumoto K, Miyazaki T, Nagayasu T (2012) Clinical and molecular analysis of synchronous double lung cancers. Lung Cancer 77:281–287. https://doi.org/10.1016/j.lungcan.2012.04.003 CrossRefPubMed

16.

Jia X, Zhang L, Wu W et al (2016) Driver mutation analysis and PD-L1 expression in synchronous double primary lung cancer. Appl Immunohistochem Mol Morphol 1. https://doi.org/10.1097/PAI.0000000000000412

17.

Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G, Biomarkers France contributors (2016) Routine molecular profileing of patients with advanced non-small-cel lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup. Lancet 387:1415–1426CrossRef

18.

Takamochi K, Oh S, Matsuoka J, Suzuki K (2012) Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer 75:313–320. https://doi.org/10.1016/j.lungcan.2011.08.007 CrossRefPubMed

19.

Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, Cheung H, Wu N, Lu N, Mao X, Yang L, Zhang J, Zhang L, Seth S, Chen H, Song X, Liu K, Xie Y, Zhou L, Zhao C, Han N, Chen W, Zhang S, Chen L, Cai W, Li L, Shen M, Xu N, Cheng S, Yang H, Lee JJ, Correa A, Fujimoto J, Behrens C, Chow CW, William WN, Heymach JV, Hong WK, Swisher S, Wistuba II, Wang J, Lin D, Liu X, Futreal PA, Gao Y (2016) Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun 7:1–8. https://doi.org/10.1038/ncomms13200 CrossRef

Title: Histopathological and molecular study for synchronous lung adenocarcinoma staging
Authors: Elsa Donfrancesco
Violaine Yvorel
François Casteillo
Marie-Laure Stachowicz
Arnaud Patoir
Olivier Tiffet
Michel Péoc’h
Fabien Forest
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keyword: Metastasis
Published in: Virchows Archiv / Issue 6/2020
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02736-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Histopathological and molecular study for synchronous lung adenocarcinoma staging

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Matrix-assisted laser desorption/ionization mass spectrometry imaging to uncover protein alterations associated with the progression of IgA nephropathy

Autopsy in adults with congenital heart disease (ACHD)

In this issue

ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology

Histotype-specific analysis of acid ceramidase expression in ovarian cancer

The autopsy debate during the COVID-19 emergency: the Italian experience